Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
Cornell University · Mahindra and Mahindra Limited (India) · +17 more institutions
Abstract
Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and differences in clinical practices across institutions raise the question of whether these associations are generalizable.
The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene sequencing. In an observational study, we examined associations between microbiota diversity and mortality using Cox proportional-hazards analysis. For stratification of the cohorts into higher- and lower-diversity groups, the median diversity value that was observed at the study center in New York was used. In the analysis of independent cohorts, the New York center was cohort 1, and three centers in Germany, Japan, and North Carolina composed cohort 2. Cohort 1 and subgroups within it were analyzed for additional outcomes, including transplantation-related death.
Citation impact
- FWCI
- 38.84
- Percentile
- 100%
- References
- 46
Authors
52- JUJonathan U. PeledCorresponding
Cornell University, Mahindra and Mahindra Limited (India)
- ALAntonio L. C. Gomes
Cornell University, Kettering University, Mahindra and Mahindra Limited (India)
- SMSean M. Devlin
Cornell University, Cancer Research And Biostatistics, Mahindra and Mahindra Limited (India)
- EREric R. Littmann
Cornell University, Kettering University, University of Chicago, Mahindra and Mahindra Limited (India)
- YTYing Taur
Cornell University, Mahindra and Mahindra Limited (India)
Topics & keywords
- Hazard ratio
- Medicine
- Transplantation
- Cohort
- Hematopoietic stem cell transplantation
- Internal medicine
- Cohort study
- Hematopoietic cell
Funding
- CCConquer Cancer Foundation
- NYNew York State Department of Health
- LFLymphoma Foundation
- SOSociety of Memorial Sloan Kettering
- PIParker Institute for Cancer Immunotherapy
- STSeres Therapeutics
- MMMochida Memorial Foundation for Medical and Pharmaceutical Research
- NINational Institutes of HealthAward: R01 AI032135
- JSJapan Society for the Promotion of ScienceAwards: 17H04206, 17K09945
- NINational Institute on AgingAwards: 2P30AG028716-11, P01-AG052359 (Project 2)
- NHNational Heart, Lung, and Blood InstituteAwards: 1R01HL124112-01A, K08HL143189-01A1, R01-HL125571, R01-HL123340
- NCNational Cancer InstituteAwards: 1R01CA228358-01, R01CA203950-01, P30 CA008748, R01-HL125571, 1R01CA228308-01, P01-CA023766 (Project 4), U01 AI124275
- NINational Institute of Allergy and Infectious DiseasesAwards: U01 AI124275, AI095706, R01 AI137269-01
- NCNational Center for Advancing Translational SciencesAward: KL2 TR001115-03
- COCenter of Innovation Program